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Abstract
The protective efficacy of the influenza matrix protein epitope 58–66 (called M1), recognized in the context of human HLA-A2
molecules, was evaluated in a HLA-A2/Kb transgenic mouse model of lethal influenza infection. Repeated subcutaneous immunizations with
M1 increased the percentage of survival. This effect was mediated by T cells since protection was abolished following in vivo depletion
of all T lymphocytes, CD8, or CD4 T cells. The survival correlated with the detection of memory CD8 splenocytes able to proliferate
in vitro upon stimulation with M1 and to bind M1-loaded HLA-A2 dimers, as well as with M1-specific T cells in the lungs, which were
directly cytotoxic to influenza-infected cells following influenza challenge. These results demonstrated for the first time that HLA-A2-
restricted cytotoxic T cells specific for the major immunodominant influenza matrix epitope are protective against the infection. They
encourage further in vivo evaluation of T cell epitopes recognized in the context of human MHC molecules.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Influenza viruses are ubiquitous pathogens which infect
both animals and humans. They cause annual worldwide
epidemics of respiratory illness, associated with excess
morbidity and mortality in susceptible people (Falsey et al.,
1995). In addition, they have a considerable economic bur-
den consecutive to related treatments, hospitalizations, and
work absenteeism (Levy, 1996).
Influenza vaccines, prepared with inactivated whole vi-
ruses or subvirion components, are well-tolerated. They
appear to be highly efficient in preventing natural infection
and/or in reducing the severity of illness caused by anti-
genically matched strains of viruses (Carman et al., 2000;
Edwards et al., 1994; Gross et al., 1995; Potter et al., 1997).
Neutralizing Abs, directed primarily to the hemagglutinin
(HA) and the neuraminidase (NA), represent the major host
defense mechanism induced upon immunization. Binding to
virions can occur at a number of different steps prior to cell
attachment, as well as at events following cell attachment,
thereby reducing the amplification and the spread of the
virus and attenuating the infection.
However, antibody responses are highly strain-specific,
while the major surface glycoproteins of influenza viruses
are subjected to frequent, accumulating mutations, called
antigenic shifts and drifts (Kilbourne et al., 1990). These
genetic variations allow the virus to escape from neutral-
ization by preexisting antibodies (Kuwano et al., 1989;
Laver et al., 1979; Moss et al., 1980). They impose updating
and readministration of influenza vaccines every year.
Evidence from animal models indicated that if the anti-
bodies play a major role in prevention of the disease, T cells
are both necessary and sufficient for recovery from influ-
enza (Bender and Small, 1992; Whitton and Oldstone,
1996). In particular, CD8 cytotoxic T cells can act as a
second line of defense by eliminating any cell in the lungs
which became infected despite the presence of neutralizing
antibodies (Cerwenka et al., 1999a,b). They are important to
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terminate infection, as demonstrated by the difficulty of
influenza-infected CD8 T cell-deficient mice to clear the
virus from their lungs (Eichelberger et al., 1991; Wells et
al., 1981).
CTLs recognize peptides in the form of 8 to 11 amino
acids derived from degraded proteins which are either syn-
thesized intracellularly or introduced directly into the cyto-
plasm (Bjorkman et al., 1987; Townsend et al., 1986). The
peptides bind to class I MHC molecules shortly after they
are synthesized. The complex is transported to the cell
surface for recognition by a specific TCR.
In humans, the CTL response is directed to numerous
surface and internal influenza proteins, with multiple
epitopes being potentially recognized, depending on the
expression of class I MHC molecules (Jameson et al., 1998;
Gianfrani et al., 2000; Robbins et al., 1997). However, the
specific immune responses detected after virus infection are
primarily directed against a small fraction of the potential
determinants, a phenomenon that is called immunodomi-
nance (Belz et al., 2000; Yewdell and Bennink, 1999).
Accordingly, the immunodominant epitope recognized by
HLA-A*0201-restricted human CTLs is composed of a
fragment of the influenza matrix protein, called M1, com-
prising amino acid residues 58 to 66 (Gotch et al., 1987).
Immunization with the exact peptide sequence corre-
sponding to a CTL epitope introduced intramuscularly by
DNA immunization (Bot et al., 1998; Fomsgaard et al.,
1999) or subcutaneously (s.c.) emulsified with a T helper
cell epitope in incomplete Freund’s adjuvant was success-
fully employed in mice to raise cellular responses which
afford a high degree of controllability (Gianfrani et al.,
2000; Valmori et al., 1994). In that respect, HLA-transgenic
mouse models provide the unique opportunity to investigate
the immunogenicity of potential CTL epitopes and the bi-
ological relevance of these responses.
Our aim was to investigate whether M1 can induce an
antiviral protective immune response in HLA-A*0201/Kb
transgenic mice. The results showed for the first time that
M1 induced a T cell-dependent influenza protection in
HLA-A2/Kb transgenic mice. This effect correlated with the
generation of M1-specific memory T cells detectable in the
spleen 3 weeks after the last immunization and the presence
of influenza-specific cytotoxic T cells in the lungs after
influenza challenge.
Results
T cell-dependent protection of HLA-A2/Kb transgenic
mice after immunization with M1
To test the protective efficacy of M1 against virus chal-
lenge, a lethal model of influenza infection was set up using
the mouse-adapted A/PR8/34 H1N1 virus, HLA-A2/Kb-
transgenic, and C57BL/6 (H-2b) mice. These mice consis-
tently suffered a progressive and dramatic weight loss re-
sulting in death within 2 weeks following intranasal (in)
instillation of the LD100 of H1N1 virus (data not shown).
HLA-A2/Kb transgenic and C57BL/6 mice were immunized
s.c. at the base of the tail two or three times with peptides
M1 or ELA as control.
Peptides were mixed with TTp30, an immunodominant T
helper cell epitope of tetanus toxin (Valmori et al., 1992),
and IFA, as described under Materials and methods, to
improve the induction of the T cell responses (Valmori et
al., 1994). Control mice for survival were treated by i.n.
instillation with a sublethal dose of H1N1 virus. Three
weeks after the last immunization, antibody responses were
investigated by ELISA. None of the mice developed detect-
able influenza antibodies in the serum (Ab titers  1.95
log10/ml) with the exception of the influenza-primed mice
(3.74  0.72 log10/ml). All the mice demonstrated the
characteristic signs of morbidity during the first week after
challenge with the LD100 of H1N1 virus. However, the weight
of the control influenza-primed mice was first stabilized and
increased thereafter (data not shown). All the influenza-
primed mice survived, as demonstrated in Fig. 1A, while the
mice previously treated with ELA went on losing weight
(data not shown) and died within 10 days (Fig. 1A).
In contrast, at this time, most of the HLA-A2/Kb trans-
genic mice immunized with M1 also survived. This effect
was dependent on the expression of HLA-A2 molecules,
since it was observed with the HLA-A2/Kb transgenic but
not with the C57BL/6 mice (not shown). In addition, the
protective effect was improved with the numbers of immu-
nizations: at day 10 postchallenge, approximately 70% of
the mice survived after two immunizations versus 90% after
three immunizations; at day 15, 50% of the mice survived
after two immunizations versus 70% after three immuniza-
tions. Thus, immunizations with M1 elicited a protective
effect against the morbidity and the mortality caused in
HLA-A2/Kb transgenic mice by a lethal H1N1 virus chal-
lenge.
Since influenza antibodies were never detected in the
serum of M1-primed mice, the role of T cells in influenza
protection was evaluated by in vivo T cell depletion. HLA-
A2/Kb transgenic mice were immunized twice with M1, as
mentioned above. Control mice received a sublethal dose of
H1N1 virus or were injected with the irrelevant peptide.
Three weeks later, the M1-immunized mice were separated
in four groups: one group untreated, and three other groups
injected with antibodies to deplete, respectively, CD8,
CD4, or both types of lymphocytes. A previous experi-
ment demonstrated that these treatments did not affect the
survival of uninfected mice or of influenza-challenged mice
which were previously immunized with Immugrip (an in-
activated influenza virus preparation which induces protec-
tive influenza antibodies, data not shown). As demonstrated
in Fig. 1B, while approximately 50% of the M1-primed/
untreated mice survived the lethal challenge at day 15, all
the mice depleted of CD8, CD4, or both T cell subsets
died within 13 days, comparing favorably with the mice
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primed with the irrelevant peptide. These results indicated
that both T lymphocyte populations were required for the
protection of HLA-A2/Kb transgenic mice against a lethal
influenza infection.
M1-specific memory T cells in HLA-A2/Kb transgenic
mice after immunization with M1
To investigate whether M1-specific memory T cells
were induced after immunizations, spleen cells were har-
vested from HLA-A2/Kb transgenic mice 3 weeks after
two s.c. injections of M1 and tested for their ability to
proliferate upon in vitro stimulation. Control mice were
immunized twice with ELA prepared, as described for
M1, with TTp30 and IFA. A significant proliferation of
spleen cells was induced for most of the M1- and ELA-
immunized mice in the presence of TTp30 (not shown).
This proliferation was due to CD4 T cells since it was
maintained after depletion of CD8 T cells (Fig. 2A), but
it was abolished after elimination of CD4 T cells (Fig.
2B). On the other hand, M1 triggered the proliferation of
spleen cells of M1- but not of ELA-immunized mice (not
shown). Interestingly, the percentage of responding mice
increased with the numbers of immunizations: approxi-
mately 55% of M1-immunized mice showed a prolifera-
tive response after two immunizations, and 70% showed
a proliferative response after three immunizations (not
shown). Proliferation to M1 was mediated by CD8 T
cells since it was maintained after CD4 T cell depletion
(Fig. 2B), but it was prevented by elimination of CD8 T
lymphocytes (Fig. 2A). No proliferation occurred with
ELA, except when the mice were previously primed with
this peptide (not shown). Thus, M1 induced specific
CD8 memory T cells which were detectable in the
spleen of HLA-A2/Kb transgenic mice 3 weeks after the
last distant immunization.
To investigate the frequency of the M1-specific T
lymphocytes, spleen cells from HLA-A2/Kb transgenic
mice immunized one, two, or three times were harvested,
numerated, and stained with anti-CD8 antibodies and
M1-loaded HLA-A2 dimers. Similar numbers of CD8 T
cells were found in the spleens in the different groups, as
shown in Fig. 3. However, the percentage of A2 dimer/
M1-stained CD8 T cells increased significantly in HLA-
A2/Kb transgenic mice after two or three immunizations
with M1, as compared with mice treated with ELA (P 
0.05). In contrast, one immunization had no detectable
effect. The frequencies of the M1-specific T cells were
very heterogeneous among the mice after two immuni-
zations, with percentage of A2 dimer/M1-positive CD8
T cells varying from 0.38 to 2.70. In contrast, the per-
centage of A2 dimer/M1-positive CD8 T cells were
closed to mean value of 0.67% after three immunizations.
Thus, the induction of M1-specific memory CD8 T cells
was improved and more homogeneous among the mice
with increasing numbers of immunizations.
Fig. 1. Protective effects of M1-immunization in HLA-A2/Kb transgenic mice HLA-A2/Kb transgenic mice were immunized by two or three s.c. injections
of M1 (M1 2 and M1 3, respectively) or ELA (ELA 3) with TTp30 and IFA. Control mice for survival were primed i.n. with a sublethal dose of H1N1
virus (H1N1). (A) Three weeks after the last immunization, the mice were challenged with the LD100 of H1N1 virus. The results of a representative
experiment out of three show the survival rate in each group containing 8 to 12 mice. (B) Three weeks after the last immunization, M1-immunized mice were
depleted of CD4 (M1-CD4), CD8 (M1-CD8), or CD4 and CD8 (M1-CD4/8) T cells as described under Materials and methods. The survival rate was
followed in each group (7–9 mice/group) after i.n. challenge with the LD100 of H1N1 virus.
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M1-specific memory cytotoxic T cells in the lungs of
HLA-A2/Kb transgenic mice following influenza challenge
Since lung CD8 T cells are critical in recovery from
lethal influenza challenge (Cerwenka et al., 1999a,b), we
investigated whether such cells and memory lymphocytes
were present in the lungs of M1-primed mice after influenza
infection. HLA-A2/Kb transgenic mice were immunized s.c.
two or three times with M1 or ELA and challenged 3 weeks
later with H1N1 virus. Lung-infiltrating cells were isolated
9 days after challenge. Those of unprimed/unchallenged
mice were used as control. The numbers of CD8 T cells
increased dramatically in the lungs of the infected mice, as
compared with unprimed/unchallenged animals (approxi-
mately by six- and sevenfolds in the ELA and the M1-
primed groups, respectively; Fig. 4). In addition, the cells
varied considerably in their level of activation and expres-
sion of surface markers specific for naive and memory T
lymphocytes. Unlike the unprimed/unchallenged mice, the
mice immunized with M1 or ELA showed a high percentage
of activated CD4 (around 75 versus 10% in unprimed/
unchallenged mice, not shown) and of CD8 T cells (80
versus 5% in unprimed/unchallenged mice; Fig. 4). Inter-
estingly, the numbers and the percentage of activated CD8
T cells were significantly increased in the mice immunized
with M1, as compared with those immunized with ELA (P
 0.05). In addition, the decrease in the percentage of naive
T cells (CD3CD62Lhigh cells) and the increase in the
percentage of memory T lymphocytes (CD3CD49d
cells) were significantly amplified in the M1 as compared
with the ELA-primed group (P  0.05). Thus, a more
efficient recruitment and/or proliferation of CD8 and
memory T cells occurred in the lungs of M1-primed mice
Fig. 2. M1-specific T cells in the spleen of HLA-A2/Kb transgenic mice.
HLA-A2/Kb transgenic mice were immunized twice s.c. with M1 (mouse
1 to 5) with TTp30 and IFA and sacrificed after 3 or 4 weeks. Spleen cells
were harvested and cultured in vitro after depletion of CD8 (A: CD4 T
cells) or CD4 (B: CD8 T cells) T cells, in medium alone (0), or with 10
g/ml of M1, TTp30, or ELA. Thymidine incorporation was measured
after 72 h of culture. The results of a representative experiment out of three
show the mean cpm SD calculated from quadriplate wells in each culture
with the responding mice.
Fig. 3. M1-specific HLA-A2-restricted T cells in the spleen of HLA-A2/Kb transgenic mice. HLA-A2/Kb transgenic mice were immunized once (1), twice
(2), or three (3) times s.c. with M1 or ELA with TTp30 and IFA and sacrificed after 3 or 4 weeks. Spleen cells were isolated and stained with anti-CD8
Abs and M1-loaded HLA-A2 dimers. The results of a representative experiment out of three show (A) the mean total numbers  SD of CD8 T cells and
(B) the mean %  SD of these cells stained with M1-loaded HLA-A2 dimers in the spleen calculated with 5–6 mice in the different groups. *P  0.05,
as compared with the ELA group.
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after influenza challenge than in mice immunized with the
irrelevant peptide.
Lung infiltrating cells were further tested for their cyto-
toxic activity. Lymphocytes were incubated, without in
vitro restimulation, with mouse target cells such as EL4
(H-2Kb) and P815 (H-2Kd) or with T2 cells (HLA-A*0201).
No cytotoxic activity was ever detected without a previous
influenza challenge (not shown), nor after challenge, when
murine cell lines, EL4 or P815 cells, were used as targets,
either untreated, infected with H1N1 virus, or pulsed with
M1 or ELA (data not shown). In contrast, as reported in
Table 1, lymphocytes of M1 (but not of ELA)-immunized
mice were directly lytic to T2 cells previously pulsed with
M1 (but not with ELA) or infected with H1N1 virus. In
addition, the percentage of mice with cytotoxic T cells in
lungs increased with the number of immunizations: approx-
imately 50% of M1-primed mice had cytotoxic cells after
two immunizations, and 80% had cytotoxic cells after three
immunizations (Table 1). These data correlated favorably
with the above reported percentages of mice showing a
proliferative cellular response upon stimulation in vitro with
M1 and having a prolonged survival after two and three
immunizations. Thus, the T cell-dependent influenza pro-
tection of HLA-A2/Kb transgenic mice correlated with the
detection of M1-specific memory T cells, in the spleen 3
weeks after the last immunization, and, after influenza chal-
lenge, in the lungs, where they became activated and di-
rectly cytotoxic to influenza-infected cells.
Discussion
Analysis of the T cell repertoire developed in HLA-A2
people after influenza infection consistently pointed out the
predominance of a CTL response generated against the
matrix protein epitope encompassing amino acid residues
58 to 66 (Gianfrani et al., 2000; Gotch et al., 1987; Jameson
et al., 1998). However, the importance of this response in
recovery from infection was completely unknown. In addi-
tion, it remained particularly difficult to investigate without
the possibility of isolating it from concomitant responses
(due to other viral antigens and other immune mechanisms)
and investing its effects on the course of an influenza in-
fection. Taking advantage of HLA-A2 transgenic mice, we
demonstrated for the first time that M1 induced a specific T
cell response with a protective activity against influenza
infection.
The HLA-A2 molecule is the most common allele in
humans and many viral or tumoral peptides able to stabilize
this class I MHC molecule as well as to induce HLA-A2-
restricted CTLs have been described (Bharadwaj et al.,
2001; Keogh et al., 2001; Zhou et al., 2001). Differences
may be observed between the strength and the hierarchy of
the responses generated to the different epitopes in trans-
genic mice compared to those seen in human following
natural infection (Bharadwaj et al., 2001). However, a pep-
tide which is recognized by human memory cytotoxic T
cells was generally also immunogenic in the corresponding
Fig. 4. T cell infiltration in the lungs of HLA-A2/Kb transgenic mice following influenza challenge. HLA-A2/Kb transgenic mice were immunized three times
s.c. with M1 or ELA with TTp30 and IFA and challenged after 3 weeks with influenza. Unprimed and unchallenged (unprimed/unchal) mice were used as
control. Lung infiltrating cells were isolated, numerated, and stained with antibodies specific for CD8, activated (CD69), naı¨ve (CD3CD62Lhigh), and
memory (CD3CD49D) T lymphocytes. The results of a representative experiment out of three show (A) the mean numbers  SD and percentage of
activated CD8 T cells, as well as (B) the mean %  SD of naı¨ve and memory lymphocytes in the lungs calculated from 6–7 mice in the different groups.
*P  0.05.
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transgenic mice. On the other hand, HLA-transgenic mice
provided an interesting model for the identification of oth-
erwise unidentified human CTL epitopes (Man et al., 1995).
In the case of influenza, M1 was shown to represent, as
in humans, a major determinant for the murine CTL re-
sponse in HLA-A2 transgenic mice, following either influ-
enza infection or immunization with the whole virus (En-
gelhard et al., 1991; Vitiello et al., 1991). Thus, it appeared
particularly convenient to use these mice to generate M1-
specific responses and to assess their influence on the course
of influenza infection. M1 immunization significantly re-
duced the morbidity and increased the survival rate after a
lethal influenza challenge. These effects correlated with the
detection of CD8 memory T cells able to recognize the
peptide upon in vitro stimulation, and to bind M1-loaded
HLA-A2 dimers in the spleen, 3–4 weeks after the last
distant immunization. In accordance with these results and
the known properties of M1, CD8 T lymphocytes were
confirmed to be critical, since survival was abolished after
in vivo depletion of these cells.
Interestingly, elimination of CD4 T cells also resulted
in mouse death, indicating that this cell subset was also
important. Helper T cells play a key role in antiviral immu-
nity with pleiotropic effects, such as cytokine secretion and
help for antibody production. They are critical for the gen-
eration of memory CD8 CTL responses, both in vitro and
in vivo (Ostankovitch et al., 1997; BenMohamed et al.,
2000; Fernando et al., 2002; La Gal et al., 2002). In addi-
tion, CD4 CTLs have been described in humans (En-
gelhard et al., 1991; Linnemann et al., 2000), as well as in
mice lacking CD8 cytotoxic T cells (Bot et al., 1998;
Epstein et al., 2000; Sherman et al., 1992). However, the in
vivo contribution of CD4 CTLs against infectious organ-
isms remains controversial. In our experiments, immuniza-
tion with M1 resulted in the generation of CD4 memory T
cells which were specific for TTp30 (the helper peptide used
during immunizations), but not for M1. TTp30-specific
CD4 T cells were also detected in ELA-primed mice (not
shown), although no protective effect was observed. Thus,
the death of M1-primed mice following depletion of CD4
T cells was likely to reflect the need of these cells in
amplification of the CD8 T cell response rather than a
direct antiviral role. This requirement agrees with previous
observations made by others (Fernando et al., 2002; La Gal
et al., 2002; BenMohamed et al., 2000) and correlates with
the necessity of using TTp30 during immunizations to gen-
erate a detectable T cell response against M1. It is further
reinforced by the notion that antiviral protection might be
more difficult to achieve without appropriate amplification
of the immune response, after immunization with a single
CD8 T cell epitope than after immunization, with a mix-
ture of several ones.
As pulmonary lymphocytes are particularly relevant to
respiratory virus clearance (MacKenzie et al., 1989; Flynn
et al., 1998; Cerwenka et al., 1999a and b), we focused our
attention on them. Flow cytometry analysis showed that
influenza challenge resulted in activation of lung infiltrating
lymphocytes, as well as in the presence of large numbers of
cells with a memory phenotype. These modifications were
seen in both ELA- and in M1-primed mice, indicating, in
accordance with earlier observations (Flynn et al., 1999;
Hogan et al., 2001), that massive recirculation, recruitment,
and/or proliferation of T cells with a memory phenotype
occurred following influenza infection. However, the per-
centages of activated and memory T cells were further
increased after immunization with M1, as compared with
ELA, suggesting that a fraction of lung lymphocytes was
specifically reactive to influenza antigens. This hypothesis
was verified by the detection in M1-primed mice only, of
lung-infiltrating T cells able to lyse, without in vitro re-
stimulation, target cells which were either pulsed with M1
or infected with H1N1 virus. Thus, M1 provided a stimu-
lation which was antigenically authentic relative to native
influenza antigens. This priming favored the recruitment
and/or the amplification and the reactivation of M1-specific
memory T cells at the site of influenza infection. This is
fully consistent with the previously documented migration
Table 1
Cytotoxic activity of lung infiltrating cells
Immunization Mouse
number
Target cells
T2 T2-H1N1 T2-M1 T2-ELA
M1 3 1 0 23.4 18 4
2 0 18.7 12 2
3 0 17.3 11.2 0
4 0 5.2 0 0
5 0 19 16 0
M1 2 1 0 nd 0 0
2 0 nd 9 0
3 0 nd 0 0
4 0 nd 0 0
5 0 nd 18 0
6 0 nd 14 0
7 0 nd 0 0
8 0 nd 11.5 0
9 0 nd 15.4 0
10 0 nd 39 0
ELA 3 1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0
5 0 0 0 0
6 0 0 0 0
7 0 0 0 0
8 0 0 0 0
Note. HLA-A2/Kb transgenic mice were immunized with two or three
s.c. injections of M1 (M1 3 and M1 2, respectively) or the irrelevant
peptide (ELA 3) in TTp30 and IFA and challenged after 3 weeks with the
LD100 of H1N1 virus. Lung infiltrating cells were isolated upon enzymatic
digestion 9 days later and assessed without in vitro restimulation for their
cytotoxic activity against HLA-A2 T2 target cells alone (T2), previously
infected with H1N1 virus (T2-H1N1), pulsed with M1 (T2-M1) or with
ELA (T2-ELA). The results of a representative experiment out of three
show the percentage of specific lysis obtained at effector/target cell ratio of
60:1, after 6 h of incubation in the presence of lung infiltrating cells of 5
to 10 mice in each group. nd, not done.
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patterns of memory T cells (Weninger et al., 2001); it is in
accordance with the role of lung CD8 T cell infiltration in
recovery from lethal influenza challenge (Cerwenka et al.,
1999b).
It was noteworthy that the CTL detected in M1-primed
mice were lytic to HLA-A2 targets but completely inef-
ficient against cells expressing murine MHC molecules.
Thus, influenza protection induced upon M1-immunization
in the HLA-A2/Kb transgenic mice was solely mediated by
HLA-A2-restricted CD8 T cells.
In conclusion, we showed that HLA-transgenic mice can
be used not only, as previously, to explore the human T cell
repertoire developed against viruses in the context of a
particular human MHC molecule, but also to evaluate in
vivo the protective efficacy of individual epitopes. In the
case of influenza, it is formerly assumed that most of the
cross-protection observed against different strains of viruses
relies on the activity of cytotoxic T cells (Sambhara et al.,
2001). It would thus be particularly interesting to identify
the epitopes derived from internal proteins which are less
abundant to the infected cell surface but also less variable
than HA or NA, to design a vaccine. This vaccine could
provide a broader and more lasting immunity. Also, a sim-
ilar strategy could be applied for identification of protective
epitopes for other virus infections and for tumor immuno-
therapy.
Materials and methods
Mice
Specific pathogen-free 7- to 8-week-old female C57BL/6
mice (H-2b) were purchased from IFFA Credo (L’Arbresle,
France); HLA-A2/Kb transgenic mice (HLA-A*0201/Kb:
6-A2KB H-2B) (Sherman et al., 1992) were acquired from
Harlan (U.S.) or from breeding cages of less than four
generations. The mice were housed and manipulated ac-
cording to French and European guidelines. They were kept
under specific pathogen-free conditions, fed rat and mouse
maintenance diet A04 (UAR, Villemoissin-sur-Orge,
France), and given water ad libitum.
Peptides Flu-M1 and TTp30 syntheses, purification, and
characterization
The peptide chains corresponding to influenza A ma-
trix M1 58 – 66 (GILGFVFTL) and a 21-mer tetanus
toxin-derived synthetic peptide (amino acid residues
948 –968: NNFTVSFWLRVPKVSASHLEQ) called
TTp30, containing an immunodominant T cell epitope for
both human and mice were synthesized by solid-phase
method on an Applied Biosystems 433A synthesizer us-
ing FMOC/tBu chemistry. The side-chain protecting
groups were trityl (Trt) for His, Asn, and Gln; tbutyl
(tBu) for Ser, Thr, and Asp; Pentamethylchromansulfo-
nyl (Pmc) for Arg, and tert-butyloxycarbonyl (tBoc) for
Lys and Trp. The crude peptides, cleaved off from resin
with trifluoroacetic acid (TFA) in the presence of scav-
engers, were lyophilized and purified by preparative re-
verse phase-high performance liquid chromatography
(RP-HPLC) as previously described (Plotnicky-Gilquin
et al., 2000). The peptides were characterized by electro-
spray-mass spectroscopy (ES-MS), their purity was
higher than 95%, as indicated by RP-HPLC. ELA (ELA-
GIGILTV), a Melan-A/MART-1 antigen immunodomi-
nant peptide analogue (Rivoltini et al., 1999), was syn-
thetized as previously described (Beck et al., 2001). It
was used throughout the experiments as an irrelevant
peptide.
Virus
The mouse-adapted A/PR8/34 (H1N1) virus was pur-
chased from the American Type Culture Collection (ATCC
VR95). It was propagated for 3 days at 35°C in the allantoic
cavity of day 10 fertilized eggs and purified on a continuous
sucrose gradient according to the method of Bachmann et al.
(1999). It was resuspended in PBS (2564 hemagglutination
Units/ml) and stored in small aliquots at 80°C until use.
The lethal doses (LD100) corresponding to 100% of death
were determined for each strain of mice.
Immunization procedures and challenge
Mice were immunized at the base of the tail once, twice,
or three times at 3-week intervals by s.c. injections of a 200
l PBS preparation containing 100 g M1 or ELA, mixed
with 100 g TTp30 and 50% v/v of incomplete Freund’s
adjuvant (IFA, Sigma). Peptides were previously solubi-
lized in DMSO at 2 mg/ml. Control mice for protection
were immunized by i.n. instillation of 0.1 HAU of purified
H1N1 virus in 50 l PBS. Three or 4 weeks after the last
immunization, mice were bled to determine H1N1 virus-
specific serum antibody titers. They were anesthetized with
2.5 ml/kg of a 4/1 mixture (v/v) of ketamine (Imalgene 500,
Rhoˆne Me´rieux, Lyon, France) and xylazine (Rompun at
2%, Bayer, Puteaux, France) before i.n. instillation of 50 l
containing the LD100 of H1N1 virus and then followed for
survival and body masses.
In vivo depletion of T cells
Depletions of CD4 and/or CD8 T cells were per-
formed as previously described (Plotnicky-Gilquin et al.,
2000). Mice were injected intraperitoneally with mAbs
GK1–5 (anti-CD4) and H35 17.2 (anti-CD8) 1 day before
challenge and again on day 2 and 3 thereafter. More than
98% of the targeted T lymphocytes were eliminated as
monitored by flow cytometry.
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ELISA
Serum influenza antibody titers were determined by
ELISA, as previously described (Power et al., 1997), except
that the plates were coated overnight at4°C with 50 l per
well of Immugrip (inactivated influenza strains 1999/2000;
Pasteur Merieux Serums et Vaccins, Lyon, France) adjusted
to 0.5 g HA protein/ml in PBS. The serum of HLA-A2/Kb
transgenic mice, immunized three times ip with 100 l
Immugrip diluted 1/3 in PBS, was used as a positive control.
Optical densities (OD) were measured at 450 nm.
Preparation of lung infiltrating cells and FACS analysis
Mice were anesthetized and exsanguinated by cardiac
puncture 9 days after challenge with the LD100 of H1N1
virus. Lung infiltrating cells were isolated upon enzymatic
digestion, numerated, and stained as reported (Plotnicky-
Gilquin et al., 1999). Cells were incubated with combina-
tions of fluorescein (FITC)- and phycoerythrin (PE)-conju-
gated mAbs to lymphocyte surface molecules CD3, CD4,
CD8, CD69, CD62L, and CD49D (Caltag, San Francisco,
CA), at previously determined optimal concentrations. They
were analyzed for two color stains using a FACSvantage
(Becton–Dickinson, Erembodegem, Belgium) after remov-
ing debris and dead cells by gating on forward and side
scatter parameters. The total numbers of CD8 T cells were
determined for each mouse by multiplying the percentage of
stained cells by the number of nucleated cells isolated from
the lungs.
T cell proliferation assay
Splenocytes were harvested 3 or 4 weeks after the last
immunization. CD4 or CD8 T cells were depleted
(95%) using a magnetic cell separator (MACS, Miltenyi
Biotex, Bergisch Gladbach, Germany), according to the
manufacturer’s instructions. Cells were washed, numerated,
and resuspended at 106 cells/ml in culture medium consist-
ing of RPMI 1640, 10% heat-inactivated fetal bovine serum,
2 mM L-glutamine, 100 U gentamicin per milliliter, and 5
105 M mercaptoethanol (all from Gibco, Cergy Pontoise,
France). They were stimulated at 5  105 cells/well in
96-well round-bottom plates (Costar, Brumath, France), for
72 h at 37°C, 5% CO2, with TTp30, M1, or ELA (1 mg/10
l DMSO), at a final concentration of 10 g/ml. All cul-
tures included wells stimulated with 5 g/ml of concanava-
lin A (ConA, Sigma) as positive controls (not shown).
Eighteen hours before the end of the culture, the cells were
pulsed with 0.25 Ci methyl 3H-thymidine (Amersham, Les
Ulis, France). They were harvested onto filters using a
semi-automatic harvester (Skaton, Lier, Norway) and the
incorporated 3H-thymidine was determined using a COBRA
II auto gammacounter (Packard Instruments, Meriden, CT).
The results were expressed in counts per minute and were
calculated from the geometric means of quadruplate cul-
tures.
Staining of cells with HLA-A2 dimers
A stock peptide solution was prepared at 100 g/ml in
DMSO. M1 was incubated overnight at 37°C together with
HLA-A2 dimers (HLA-A2: Ig protein, Pharmingen) at a 50
molar excess, in the presence of 2-microglobulin (stock
solution at 250 g/ml), i.e., 1 g dimer, 0.23 g M1, and
0.5 g 2-microglobulin for each test sample. Spleen cells
(106) were incubated in 100 l RPMI 1640–10% FCS with
10 l human IgG (stock solution: 200 g/ml) for 10 min at
RT. After one wash, 10 l RPMI containing M1-loaded
dimers, or empty dimers as control, were added to the cell
pellet and samples were incubated for 60 min at 4°C, under
agitation. After two washes in PBS–0.2% BSA–50 M
EDTA, cells were resuspended in 100 l PBS–1% bovine
serum albumin–0.01% NaN3 and incubated for 30 min at
4°C with 0.5 g of a PE-conjugated rat anti-mouse IgG1 Ab
(Pharmingen). After washes in PBS–0.2% BSA–50 M
EDTA, cells were resuspended in 100 l PBS–1% BSA–
0.01% NaN3 and incubated for 30 min at 4°C with 0.5 g
of FITC-conjugated rat anti-mouse CD8 Abs (Pharmingen).
After washes, samples were transferred into FACS tubes
and analyzed on a FACSvantage SE flow cytometer (Bec-
ton–Dickinson). Fifty to 100 thousand CD8 cells were
analyzed for each sample, after gating lymphocytes on FCS-
SSC parameters. The total numbers of CD8 T cells in the
spleens were calculated by multiplying the percentage of
cells stained with the anti-CD8 Abs by the total numbers of
nucleated cells in the spleen. The percentage of A2 dimer/
M1-positive CD8 T cells were corrected by subtraction of
the percentage of cells stained with empty dimers.
Cytotoxicity assay
Cytotoxic activities were measured using a 51Cr release
assay. Human T2 (Tap/, HLA-A*0201) or murine EL4
(H-2Kb) and P815 (H-2Kd) cells were used as targets, either
untreated or after infection with H1N1 virus, or incubated
overnight at 37°C with peptides at 50 g/ml in OptiMEM-1
(Life Technology, Gibco, no.; 31985-047). The expression
of viral antigens was confirmed by staining of the cells with
a mouse anti-H1N1 virus serum. The fixation of peptides on
T2 cells was revealed by stabilization of class I MHC
molecules on the cell surface after staining with an anti-
HLA class I Ab (MA2.1, no. HB54, ATCC). Target cells
were washed, numerated, and labeled by a 2-h incubation,
with 100 Ci Na51CrO4 (Amersham) per 106 cells. After
washes, target cells were mixed with lung infiltrating cells at
an effector/target cell ratio of 60:1 in 96-well plates and
incubated at 37°C, 5% CO2, for 6 h. Spontaneous and
maximum 51Cr releases were obtained in wells containing
the target cells in medium or with 100 l Triton X-100
diluted 1/100 in water, respectively. After plate centrifuga-
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tion, a 100-l sample of supernatant from each cell mixture
was counted in a Packard 1900CA-Tricarb betacounter to
determine the amount of 51Cr released from target cells. The
percentages of specific lysis were calculated as follows: %
specific lysis  (experimental release  spontaneous re-
lease)/(total release  spontaneous release)  100.
The spontaneous release for T2 and murine target cells in
medium alone never exceeded 15 and 20%, respectively.
Statistical analyses
Statistical analyses were done using the t-test and Kol-
mogorov–Smirnov test (for low sample numbers) of the
Statigraphic software program (Manugistics, Rockville,
MD).
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